Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy

Publication date: Available online 25 February 2020Source: Actas Urológicas Españolas (English Edition)Author(s): G. del Pozo Jiménez, F. Herranz Amo, J.A. Arranz Arija, E. Rodríguez Fernández, D. Subirá Ríos, E. Lledó García, G. Bueno Chomón, M.J. Cancho Gil, J. Carballido Rodríguez, C. Hernández Fernández
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research

Related Links:

Rationale: Signet ring cell carcinoma of the stomach is prone to relapse and metastasis after traditional surgical treatment, and the prognosis is also poor. We improved the concept of treatment and conducted cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) combined with intraperitoneal (IP) and intravenous (IV) chemotherapy for a gastric signet-cell carcinoma patient. Patient concerns: A 65-year-old male patient with complaint of intermittent hematemesis for over 10 days was referred to our hospital for treatment. The patient developed hematemesis of 800 mL without obvious causes o...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
In this study, we investigated the ability of teriflunomide to act as an antineoplastic drug by examining the effects of teriflunomide treatment on HCC cells. Teriflunomide strongly inhibited the proliferation of HCC cells, induced cell apoptosis and induced cell accumulation in S phases of the cell cycle. LncRNA and mRNA expression profiles of HCC cells treated with teriflunomide compared with controls were performed by using microarray analysis. For comparison, the differentially expressed mRNAs were annotated by using gene ontology (GO) and pathway analyses. The microarray revealed that 2085 lncRNAs and 1561 mRNAs diffe...
Source: Journal of Molecular Histology - Category: Laboratory Medicine Source Type: research
Conditions:   Metastatic Bladder Urothelial Carcinoma;   Refractory Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8 Interventions:   Drug: Docetaxel;   Drug: Eribulin Mesylate;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Sharma P, Basu S Abstract Metastatic neuroendocrine neoplasms (NEN) of the parotid gland, with discordant histopathology reports between primary parotid tumor (poorly differentiated small cell neuroendocrine carcinoma) and large hepatic metastasis (atypical carcinoid with moderately differentiation status, Ki-67 15-20%), and the value of dual tracer PET-CT imaging (68Ga-DOTATATE and 18F-FDG) features in such clinical setting are illustrated. Minimal 68Ga-DOTATATE and high grade 18FDG uptake of the lesions indicated a poor differentiation status helped in clarifying tumor biology, with its potential implica...
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research
Hynninen J Abstract OBJECTIVE: Human epididymis protein 4 (HE4) is a validated, complementary biomarker to cancer antigen 125 (CA125) for high grade serous ovarian carcinoma (HGSC). Currently, there are insufficient data on the utility of longitudinal HE4 measurement during HGSC treatment and follow up. We set to provide a comprehensive analysis on the kinetics and prognostic performance of HE4 with serial measurements during HGSC treatment and follow up. METHODS: This prospective study included 143 patients with advanced HGSC (ClinicalTrials.gov identifier: NCT01276574). Serum CA125 and HE4 were measured at...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
ConclusionSince sorafenib is becoming increasingly important in HCC treatment clinically, this study will help us understand the potential targets and eliminate diverse existing side effects of it as well as explore several potential clinical biomarkers with comprehensive analysis of differential gene expression profile.
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
ConclusionsDurvalumab and tremelimumab demonstrated clinical benefit with a prolonged survival and manageable toxicity profile in patients with recurrent or metastatic PSC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
The objective of this study is to report the cutaneous side effects of EGFR inhibitors and to share treatment methods for such side effects.Materials and method: In this prospective study, 59 patients using EGFR due to breast and colorectal carcinoma at the oncology unit of Haseki Training and Research hospital were assessed. The patients for whom EGFR was initiated were examined at the beginning of the treatment at weeks 1 and 2, their demographic characteristics were recorded, and the patients who developed a skin rash were followed up from the onset of the lesion. The papulopustular side effects that developed in the pa...
Source: Cutaneous and Ocular Toxicology - Category: Toxicology Authors: Tags: Cutan Ocul Toxicol Source Type: research
Nasopharyngeal carcinoma (NPC) is rare worldwide but highly prevalent in southern China [1]. Roughly 70% of newly diagnosed cases present with locoregionally advanced NPC (LANPC) [2], whose management remains a challenge as treatment failures occur in nearly 30% of them [3,4]. Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) is currently widely recommended for LANPC due to its high efficacy and acceptable tolerance [5 –7].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Conclusion: Although the number of study population was small, our results suggest that PCE is feasible and potentially effective for R/M NPC, with a 58.3% response rate and 4.1-month PFS. Further prospective evaluation is warranted.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Urology & Nephrology